Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany

International Journal of Technology Assessment in Health Care

Volumn 26, Issue 1, 2010, Pages 62-70

  Adarkwah, Charles Christian ^a   Gandjour, Afschin ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b RICE UNIVERSITY   (United States)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Cost effectiveness; Decision modeling; Screening; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DECISION MODELING; TYPE 2 DIABETES MELLITUS;

COMPUTER SIMULATION; COST EFFECTIVENESS; COSTS; DIAGNOSIS; ENZYMES; HEALTH INSURANCE; MULTIVARIANT ANALYSIS; SENSITIVITY ANALYSIS;

COST BENEFIT ANALYSIS;

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ALBUMINURIA; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COUGHING; DISEASE COURSE; DISEASE SIMULATION; EARLY INTERVENTION; GERMANY; HEALTH INSURANCE; HIDDEN MARKOV MODEL; KIDNEY DISEASE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; DIABETIC NEPHROPATHY; ECONOMICS; HUMAN; MIDDLE AGED; PROBABILITY; TIME; URINE;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GERMANY; HUMANS; MARKOV CHAINS; MIDDLE AGED; TIME FACTORS;

EID: 77949900003     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990584     Document Type: Article

References (53)

1. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576-1581.
2. Arnesen T, Trommald M. Roughly right or precisely wrong? Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy. 2004;9:43-50.
3. Barnett AH, Bain SC, Bouter P, et al; for the Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med. 2004;351:1952-1961.
4. Bertoni AG, Krop JS, Anderson GF, et al. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25:471-475.
5. Bleichrodt H, Johannesson M. Standard gamble, time trade-off and rating scale: Experimental results on the ranking properties of QALYs. J Health Econ. 1997;16:155-175.
6. Braun S, Prenzler A, Mittendorf T, et al. Appraisal of resource use in the German health-care system from the perspective of the statutory health insurance [in German]. Gesundheitswesen. 2009;71:19-23.
7. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: Use of the Dirichlet distribution in a Bayesian framework. Med Decis Making. 2003;23:341-350.
8. Brown GC, Brown MM, Sharma S, et al. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14:18-24.
9. Bundesministerium für Gesundheit und Soziale Sicherung, Krankheitskosten nach Alter und Geschlecht, 2002. http://www.gbebund.de/ (accessed May 23, 2006).
10. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and metaanalysis. Lancet. 2005;366:2026-2033.
11. Churchill DN, Torrance GW, Taylor DW, et al. Measurement of quality of life in end-stage renal disease: The time trade-off approach. Clin Invest Med. 1987;10:14-20.
12. Comper WD, Osicka TM, Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis. 2003;41:336-342.
13. Cook DJ, Guyatt GH. Interpreting, integrating, and individualizing evidence about the prevention of diabetic nephropathy. Ann Intern Med. 1999;131:707-708.
14. Dolan P, Gudex C, Kind P, et al. Valuing health states: A comparison of methods. J Health Econ. 1996;15:209-231.
15. Frei U, Schober-Halstenberg HJ. Nierenersatztherapie in Deutschland. Berichtüber Dialysebehandlung und Nierentransplantation in Deutschland 2005/2006 Berlin:Quasi-Niere; 2006.
16. Gandjour A, Kleinschmit F, Lauterbach KW; INTERCARE International Investigators. European comparison of costs and quality in the prevention of secondary complications in Type 2 diabetes mellitus (2000-2001). Diabet Med. 2002;19:594-601.
17. Giani G, Janka HU, Hauner H, et al. Epidemiologie and Verlauf desDiabetesmellitus in Deutschland. In: ScherbaumWA,Kiess W, eds. Evidenzbasierte Diabetes-Leitlinien DDG. Deutsche Diabetes-Gesellschaft; 2004.
18. Glaeske G, Jahnsen K. GEK-Arzneimittel-Report 2007. http://media.gek.de/ downloads/magazine/GEK-Arzneimittel- Report-2007.pdf (accessed October 1, 2008).
19. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensinconverting enzyme inhibitors. Ann Intern Med. 1999;131:660-667.
20. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine.NewYork:OxfordUniversity Press; 1996.
21. Guideline of the American Diabetes Association (ADA). Nephropathy in Diabetes. Diabetes Care. 2004;27(Suppl):79S- 83S.
22. Hasslacher C, Gandjour A, et al. Diagnostik, Therapie und Verlaufskontrolle der Diabetischen Nephropathie. In: Scherbaum WA, LauterbachKW,RennerR, eds. EvidenzbasierteDiabetes- Leitlinien DDG. Deutsche Diabetes Gesellschaft; 2000.
23. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in peoplewith diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
24. John JA,Whitaker D, Johnson DG. Statistical thinking in business. 2nd ed. Boca Raton, FL: Chapman & Hall/CRC; 2006.
25. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Guideline 11: Use of angiotensin-converting- enzyme inhibitors and angiotensin receptor blockers in CKD. Am J Kidney Dis. 2004;43(Suppl 1):S1-S290.
26. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: A metaregression analysis. Ann Intern Med. 1993;118:129-138.
27. Kassenärztliche Bundesvereinigung Berlin. Einheitlicher Bewertungsmaßstab für ärztliche Leistungen. Berlin; 13.07.2006.
28. Koester I, von Ferber L, Ihle P, et al. The cost burden of diabetes mellitus: The evidence from Germany-the CoDiM Study. Diabetologia. 2006;49:1498-1504.
29. Koopman RJ, Mainous AG III, Diaz VA, et al. Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med. 2005;3:60-63.
30. Kuntz KM, Weinstein MC. Modelling in economic evaluation. In: Drummond M, McGuire A, eds. Economic evaluation in health care. Merging practice with theory. Chapter 7. Oxford: Oxford University Press; 2005:141-171.
31. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
32. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
33. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29.
34. McIntosh A, Hutchinson A, Marshall S, et al. Clinical guidelines and evidence review for type 2 diabetes. Renal disease: Prevention and early management. Sheffield: ScHARR, University of Sheffield; 2002.
35. Nebel M. Costs of renal replacement therapies in Germany in 1999. Nieren- und Hochdruckkrankheiten. 2002;3:85-92.
36. NeubauerG,BreuM, PommerW. Prospective cost-comparison study on centre haemodialysis and peritoneal dialysis in Germany. München: ifG Institut für Gesundheitsökonomik; 2000.
37. Niskanen LK, Penttila I, Parviainen M, et al. Evolution, risk factors, and prognostic implications of albuminuria in NIDDM. Diabetes Care. 1996;19:486-493.
38. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
39. Rosen AB, Hamel BH,Weinstein MC, et al. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
40. Rote Liste: Arzneimittelverzeichnis für Deutschland. BPI Service GmbH, ed. Aulendorf: Editio Cantor; 2005.
41. Rote Liste Service GmbH. Rote Liste: Arzneimittelverzeichnis für Deutschland [online]. http://www.rote-liste.de (accessed October 1, 2008).
42. Scheid DC, McCarthy LH, Lawler FH, et al. Screening for microalbuminuria to prevent nephropathy in patients with diabetes: A systematic review of the evidence. J Fam Pract. 2001;50:661-668.
43. Schroeder A, Heiderhoff M, Koebberling J. Determination of albuminuria in the urine of diabetics for prevention and control of diabetic nephropathy. Köln: DIMDI; 2005.
44. Selbstverwaltung für German Refined-Diagnosis Related Groups. G-DRG V2006 Browser 2006 [online]. http://www.gdrg. de/ (accessed November 24, 2006).
45. Statistisches Bundesamt. Sterbetafel 2005/2007. http://www. destatis.de/jetspeed/portal/cms/ (accessed October 1, 2008).
46. Statistisches Bundesamt. Verbraucherpreisindex für Deutschland. http://www.destatis.de/indicators/d/vpi101jd.htm (accessed August 23, 2007).
47. SteinesW, PiehlmeierW, Schenkirsch G, et al. Effectiveness of a disease management programme for patients with type 2 diabetes mellitus and albuminuria in primary care-the PROSIT project (Proteinuria Screening and Intervention). Exp Clin Endocrinol Diabetes. 2004;112:88-94.
48. Strippoli GFM, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;CD006257.
49. Strippoli GFM, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2005;CD004136.
50. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulindependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
51. U.S. Department of Health and Human Services. Third national health and nutrition examination survey, 1988-1994, NHANES III Household Adult and Laboratory Data Files (CD-ROM). Public use data file documentation number 76200. Hyattsville, MD: U.S. Department of Health and Human Services. National Center for Health Statistics, Centers for Disease Control and Prevention; 1996.
52. U.S. Rena Data System. USRDS 2001 annual data report: Atlas of ESRD in theUnited States.Bethesda, MD: National Institutes of Diabetes and Digestive and Kidney Diseases; 2001.
53. VA/DoD clinical practice guideline for the management of diabetes mellitus (2003). http://www.guideline.gov/summary/ summary.aspx?doc-id=5185 (accessed August 21, 2007).